A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GORTEC (GROUPE D'ONCOLOGIE READIOTHÉRAPIE TÊTE ET COU)
- Phase: III
- Execution start: 30/06/2020
- End of execution: 31/07/2027
- PI: JOAQUINA MARTINEZ GALAN